HomeInsightsStock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Last Updated on: May 06, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1503 as of 06 May 09:20.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 48.1 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 92029 crore on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Mankind Pharma Ltd for the Dec '24 is ₹ 3310 crore as compare to the Sep '24 revenue of ₹ 3188 crore. This represent the growth of 3.83%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Mankind Pharma Ltd for the Dec '24 is ₹ 910.56 crore as compare to the Sep '24 ebitda of ₹ 962.04 crore. This represent the decline of -5.35%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 384.52 crore over 7 quarters. This represents a CAGR of -13.36% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Mankind Pharma Ltd News Hub

News

Mankind Pharma slides after Q3 PAT slips 16% YoY to Rs 380 cr

However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in t...

Read more

24 Jan 2025 12:12

News

Mankind Pharma to table results

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 23 January ...

Read more

13 Jan 2025 17:30

News

Mankind Pharma allots 1.19 cr equity shares under QIP issue

Mankind Pharma has allotted 1,19,04,761 equity shares of face value of Re 1 each to the el...

Read more

20 Dec 2024 14:17

News

Mankind Pharma raises nearly Rs 3,000 crore from eligible institutional buyers via QIP issue

The company has approved the allocation of 1,19,04,761 equity shares at an issue price of ...

Read more

20 Dec 2024 11:52

News

Mankind Pharma edges higher after board approves opening of Rs 3,000 crore QIP issue

The company's board authorized and declared the opening of the issue on Monday, 16 Decembe...

Read more

17 Dec 2024 10:07

News

Mankind Pharma Ltd rises for third consecutive session

Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2...

Read more

02 Dec 2024 13:05

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Cipla Ltd or Mankind Pharma Ltd?

Market cap of Cipla Ltd is 124,626 Cr while Market cap of Mankind Pharma Ltd is 99,678 Cr

What are the key factors driving the stock performance of Cipla Ltd and Mankind Pharma Ltd?

The stock performance of Cipla Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Mankind Pharma Ltd?

As of May 6, 2025, the Cipla Ltd stock price is INR ₹1543.1. On the other hand, Mankind Pharma Ltd stock price is INR ₹2416.0.

How do dividend payouts of Cipla Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Cipla Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions